Trial · NCT07605429
BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.
NCT07605429, Phase 3, Recruiting, OHB Pediatrics Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. Trials, record NCT07605429. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07605429
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.
- NCT number
- NCT07605429
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 165 participants, estimated
- Lead sponsor
- OHB Pediatrics Ltd.
- Conditions
- Angelman Syndrome
- Interventions
- rugonersen, Sham procedure
- First posted
- 2026-05-26
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the Bayley-4 cognition and/or expressive communication raw scores without caregiver input at Week 56. | Baseline to week 56 | The Bayley-4 is a performance-based assessment of developmental functioning of five core battery scales: cognitive, language (two subtests: expressive and receptive communication), motor (two subtests: gross and fine motor), social-emotional, and adaptive behavior. Change from baseline in the raw scores of the cognition and/or expressive communication scales of the Bayley-4, without caregiver input, higher change reflects a better outcome of the core scales. |
| Secondary | Symptoms of Angelman Syndrome - Clinician Global Impression of Change (SAS-CGI-C) overall at Week 56. | Week 56 | The SAS-CGI-C is a Symptoms of Angelman Syndrome - Clinician Global Impression of Change that has been developed for Angelman Syndrome. The SAS-CGI-C is a nine domain, clinician-rated measure, which assesses the clinician's impression of the severity of a participant's condition ranging from "very much improved" (1) to "very much worse" (7). |
| Secondary | Change from baseline in electroencephalogram (EEG) delta-band power at Week 56. | Week 56 | Change from baseline in electroencephalogram (EEG) delta-band power at Week 56. |
| Secondary | Incidence of serious adverse events (SAEs). | Week 60 | Incidence of serious adverse events (SAEs). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07605429
GET https://conductscience.org/api/trials/v1/NCT07605429/registered